CA12
Carbonic anhydrase 12
As of the edition of 20 October 2026, CA12 (carbonic anhydrase 12, UniProt O43570) has 3 drugs tested at it and 5 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O43570
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 40
- Disease areas
- Lungs and airways; Nervous system; Heart and blood vessels; Nutrition and metabolism; Eye; Inherited and neonatal; Mental health; Hormones
- Registered trials of its drugs
- 91
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Acetazolamide | Marketed | Phase 4 | none listed |
| SLC-0111 | Stopped | Phase 2 | none listed |
| Dichlorphenamide | Marketed | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 3 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| União Química Farmacêutica Nacional S/A | Route B |
| Welichem Biotech | Route A |
The other 3 companies at CA12
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at CA12, ranked, with the facts behind eachRequest access. Nothing is shown until you do.